Huakang Biomedical Holdings Company Limited provided group earnings guidance for the year ended 31 December 2023. Based on the information currently available to the board of directors of the Company, including the preliminary review of the latest unaudited consolidated management accounts of the Group, the Board informed the shareholders of the Company and potential investors that the Group is expected to record a loss attributable to owners of the Company of not more than RMB 5.8 million for the year ended 31 December 2023 (the "Current Year") as compared with approximately RMB 3.1 million for the year ended 31 December 2022 (the "Corresponding Year").